STOCK TITAN
  1. Home
  2. News
  3. UCBJY

UCB SA - UCBJY STOCK NEWS

IMPACT
SENTIMENT
UCBJY : OTC
First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022
clinical trial
IMPACT
SENTIMENT
UCBJY : OTC
UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022
clinical trial
IMPACT
SENTIMENT
UCBJY : OTC
UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis
IMPACT
SENTIMENT
UCBJY : OTC
JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA® (fenfluramine) Oral Solution in Lennox-Gastaut Syndrome (LGS)
clinical trial
IMPACT
SENTIMENT
UCBJY : OTC
UCB Showcases Strength of Broad Neurology Portfolio at 74th American Academy of Neurology (AAN) Annual Meeting
IMPACT
SENTIMENT
UCBJY : OTC
FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)
fda approval
IMPACT
SENTIMENT
UCBJY : OTC
New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting
IMPACT
SENTIMENT
UCBJY : OTC
UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results
clinical trial
IMPACT
SENTIMENT
UCBJY : OTC
Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study
clinical trial
IMPACT
SENTIMENT
UCBJY : OTC ZGNX : Nasdaq
UCB to acquire Zogenix
acquisition
Stock UCBJY logo
UCB SA

OTC:UCBJY

UCBJY Rankings

#794 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

UCBJY Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Pharmaceuticals: Major, Health Technology, Manufacturing, Medicinal and Botanical Manufacturing
Belgium
Anderlecht